GLIS2 and CCND1 expression levels in breast cancer patients
dc.authorscopusid | 57197814420 | en_US |
dc.authorwosid | CFW-1256-2022 | en_US |
dc.contributor.author | Sadeghi, Minoosh | |
dc.contributor.author | Gholizadeh, Majid | |
dc.contributor.author | Safataj, Neda | |
dc.contributor.author | Tahmasebivand, Mahsa | |
dc.contributor.author | Mohajeri, Gholamreza | |
dc.contributor.author | Lotfi, Hajie | |
dc.contributor.author | Bostanabad, Saber Yari | |
dc.contributor.author | Safar, Behnaz | |
dc.contributor.author | Salehi, Mansoor | |
dc.date.accessioned | 2024-01-31T08:19:26Z | |
dc.date.available | 2024-01-31T08:19:26Z | |
dc.date.issued | 2023 | en_US |
dc.department | Fakülteler, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmakoloji Ana Bilim Dalı | en_US |
dc.description.abstract | Breast cancer (BC) is the most prevalent cancer in women, with increasing incidence and death rates in recent years. Disruptions of different signaling pathways partially cause breast cancer. Hence, different genes through particular pathways are involved in BC tumorigenesis. METHODS: In this study, we evaluated the expression level of GLIS2 and CCND1 genes in 50 patients. Also, in-silico analyses were used to enrich related signaling pathways involving the mentioned genes. RESULTS: The results showed an increased expression level of Cyclin D1 and decreased expression level of GLIS2 in BC patients. Moreover, a relationship between aberrant expression levels of GLIS2 and CCND1 and BC development was determined. CONCLUSION: These observations could help uncover new therapeutic targets for treating patients with BC in the progressive stage. | en_US |
dc.identifier.citation | Sadeghi, M., Gholizadeh, M., Safataj, N., Tahmasebivand, M., Mohajeri, G., Lotfi, H., Bostanabad, S. Y., Safar, B., & Salehi, M. (2023). GLIS2 and CCND1 expression levels in breast cancer patients. Breast Disease, 42(1), pp. 251–259. https://doi.org/10.3233/BD-220068 | en_US |
dc.identifier.doi | 10.3233/BD-220068 | en_US |
dc.identifier.endpage | 259 | en_US |
dc.identifier.issn | 0888-6008 | |
dc.identifier.issn | 1558-1551 | |
dc.identifier.issue | 1 | en_US |
dc.identifier.pmid | PMID: 37574724 | en_US |
dc.identifier.scopus | 2-s2.0-85168059642 | en_US |
dc.identifier.scopusquality | Q4 | en_US |
dc.identifier.startpage | 251 | en_US |
dc.identifier.uri | https://doi.org/10.3233/BD-220068 | |
dc.identifier.uri | https://hdl.handle.net/20.500.13055/646 | |
dc.identifier.volume | 42 | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.institutionauthor | Bostanabad, Saber Yari | |
dc.language.iso | en | en_US |
dc.publisher | IOS Press | en_US |
dc.relation.ispartof | Breast Disease | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Breast Cancer | en_US |
dc.subject | CCND1 | en_US |
dc.subject | GLIS2 | en_US |
dc.subject | Signaling Pathway | en_US |
dc.title | GLIS2 and CCND1 expression levels in breast cancer patients | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication |
Dosyalar
Orijinal paket
1 - 1 / 1
Kapalı Erişim
- Ä°sim:
- GLIS2 and CCND1 expression levels in breast.pdf
- Boyut:
- 733.8 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin / Full Text
Lisans paketi
1 - 1 / 1
Kapalı Erişim
- Ä°sim:
- license.txt
- Boyut:
- 1.44 KB
- Biçim:
- Item-specific license agreed upon to submission
- Açıklama: